Vericel (VCEL) closed at $58.65 on November 18, 2026, up 1.3% from the previous close, on volume of 790,700 shares (30-day average 765,897).
Data as of November 18, 2026.
TipRanks (Mon, 16-Nov 8:10 AM ET)
Vericel Earnings Call Signals Broad Growth and Stronger Profits
TipRanks (Sun, 15-Nov 7:08 PM ET)
Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026
Globe Newswire (Fri, 13-Nov 8:30 AM ET)
Vericel raises 2026 guidance after a record quarter with 30% adjusted EBITDA margin
Market Chameleon (Thu, 5-Nov 6:08 AM ET)
Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
Globe Newswire (Thu, 5-Nov 7:55 AM ET)
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026
Globe Newswire (Thu, 22-Oct 8:30 AM ET)
Wound Care Stocks Are Posting Double-Digit Growth. Here's Why.
Globe Newswire (Tue, 6-Oct 9:06 AM ET)
Globe Newswire (Tue, 22-Sep 7:00 AM ET)
Globe Newswire (Tue, 8-Sep 8:30 AM ET)
Vericel Raises 2026 Guidance After Record Revenue Growth and Margin Expansion
Market Chameleon (Thu, 7-May 5:13 AM ET)
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Vericel trades on the NASDAQ stock market under the symbol VCEL.
As of November 18, 2026, VCEL stock price climbed to $58.65 with 790,700 million shares trading.
VCEL has a beta of 0.05, meaning it tends to be less sensitive to market movements. VCEL has a correlation of 0.00 to the broad based SPY ETF.
VCEL has a market cap of $3.00 billion. This is considered a Mid Cap stock.
Last quarter Vericel reported $85 million in Revenue and $.27 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.22.
In the last 3 years, VCEL traded as high as $63.00 and as low as $28.95.
The top ETF exchange traded funds that VCEL belongs to (by Net Assets): IJR, IWM, VTI, XBI, IWO.
VCEL has outperformed the market in the last year with a price return of +48.7% while the SPY ETF gained +10.8%. VCEL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +34.5% and +42.7%, respectively, while the SPY returned -5.3% and -3.2%, respectively.
VCEL support price is $56.18 and resistance is $59.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VCEL shares will trade within this expected range on the day.